<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01264549</url>
  </required_header>
  <id_info>
    <org_study_id>STRAWINSKI</org_study_id>
    <nct_id>NCT01264549</nct_id>
  </id_info>
  <brief_title>Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients (STRAWINSKI)</brief_title>
  <acronym>STRAWINSKI</acronym>
  <official_title>Stroke Adverse Outcome is Associated With Nosocomial Infections: PCTus- Guided Antibacterial Therapy in Severe Ischemic Stroke Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brahms AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Development of stroke associated pneumonia (SAP) has a detrimental effect on stroke outcome.
      Biomarker-guided antibiotic treatment of patients at high risk for pneumonia may help to
      improve stroke outcome. Therefore, the investigators will evaluate whether intensified
      infection monitoring via Procalcitonin guiding an early standardized antibiotic treatment
      improves functional outcome after stroke compared with standard therapy based on current
      guidelines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin scale (mRS 0-6) score 0-4 adjusted for baseline modified Rankin score</measure>
    <time_frame>3 months after onset of symptoms (stroke)</time_frame>
    <description>To assess the proportion of patients with a modified Rankin scale (mRS 0-6) score 0-4 at day 90 adjusted for baseline modified Rankin score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients receiving any antibiotic therapy</measure>
    <time_frame>3 months after onset of symptoms (stroke)</time_frame>
    <description>To assess the proportion of patients receiving any antibiotic therapy for any duration within 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin scale adjusted for baseline modified Rankin score</measure>
    <time_frame>3 months after onset of symptoms (stroke)</time_frame>
    <description>To assess the Modified Rankin scale at day 90 adjusted for baseline modified Rankin score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index adjusted for baseline Barthel Index</measure>
    <time_frame>3 months after onset of symptoms (stroke)</time_frame>
    <description>To assess the Barthel Index (BI 0-100) at day 90 adjusted for baseline Barthel Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin scale (mRS) score 0-4 adjusted for baseline modified Rankin score</measure>
    <time_frame>6 months after onset of symptoms (stroke)</time_frame>
    <description>To assess the proportion of patients with a modified Rankin scale (mRS) score 0-4 at day 180 adjusted for baseline modified Rankin score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin scale adjusted for baseline modified Rankin score</measure>
    <time_frame>6 months after onset of symptoms (stroke)</time_frame>
    <description>To assess the modified Rankin scale at day 180 adjusted for baseline modified Rankin score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index adjusted for baseline Barthel Index</measure>
    <time_frame>6 months after onset of symptoms (stroke)</time_frame>
    <description>To assess the Barthel Index at day 180 adjusted for baseline Barthel Index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days alive and out of hospital</measure>
    <time_frame>3 months after onset of symptoms (stroke)</time_frame>
    <description>To assess the days alive and out of hospital at day 90.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first event of death, re-hospitalization or recurrent stroke</measure>
    <time_frame>within 6 months after onset of symptoms (stroke)</time_frame>
    <description>To assess the time to first event of death, re-hospitalization or recurrent stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of events of post stroke infections</measure>
    <time_frame>within 7 days after onset of symptoms (stroke)</time_frame>
    <description>To assess the proportion of events of post stroke infections to day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of events of post stroke infection or death</measure>
    <time_frame>within 7 days after onset of symptoms (stroke)</time_frame>
    <description>To assess the proportion of events of post stroke infection or death to day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medium number of days with fever (≥ 37,5°C) per patient</measure>
    <time_frame>within 7 days after onset of symptoms (stroke)</time_frame>
    <description>To assess the medium number of days with fever (≥ 37,5°C) per patient to day 7.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke volume analysis</measure>
    <time_frame>6 months after onset of symptoms (stroke)</time_frame>
    <description>To investigate the effect of an early PCT-guided antiinfective therapy on stroke volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>on discharge</time_frame>
    <description>To assess the length of hospital stay after acute stroke.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital discharge disposition</measure>
    <time_frame>on discharge</time_frame>
    <description>To assess the disposition on hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>shift analysis of the mRS</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>PCT guided arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor</intervention_name>
    <description>The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics</description>
    <arm_group_label>PCT guided arm</arm_group_label>
    <other_name>Procalcitonin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥18 years

          -  stroke onset within the last 40 hours before randomisation

          -  clinical diagnosis of a severe (NIHSS &gt; 9), non-lacunar stroke in the middle cerebral
             artery territory

          -  consent given by the patient or by his/her legitimate representative where patients
             are incapable of giving consent themselves

        Exclusion Criteria:

          -  CT evidence of an intracerebral haemorrhage or a lacunar infarct as the probable cause
             of the current illness

          -  Antibiotic use within the last 10 days

          -  Suspected life expectancy of &lt; 3 months

          -  Participation in other interventional trials (on pharmaceuticals or medical devices)

          -  Pregnancy, lactation

          -  Pre-stroke mRS score ≥ 4
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Meisel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University Berlin (Center for Stroke Research Berlin CSB &amp; NeuroCure Clinical Research Center NCRC)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Anker, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité University Berlin (Dept of Cardiology)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charite University (Center for Stroke Research Berlin CSB &amp; NeuroCure Clinical Research Center NCRC)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unfallkrankenhaus Berlin Neurologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Auguste Viktoria Klinikum Neurologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Neukölln Neurologie</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) Neurologie</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Hotter B, Jegzentis K, Steinbrink J, Schmidt WU, Endres M, Meisel A, Haverkamp W, Jungehulsing GJ. Impact of selection criteria on recruitment in an interventional stroke trial. Cerebrovasc Dis. 2013;36(5-6):344-50. doi: 10.1159/000355493. Epub 2013 Oct 30.</citation>
    <PMID>24192450</PMID>
  </results_reference>
  <results_reference>
    <citation>Ulm L, Hoffmann S, Nabavi D, Hermans M, Mackert BM, Hamilton F, Schmehl I, Jungehuelsing GJ, Montaner J, Bustamante A, Katan M, Hartmann A, Ebmeyer S, Dinter C, Wiemer JC, Hertel S, Meisel C, Anker SD, Meisel A. The Randomized Controlled STRAWINSKI Trial: Procalcitonin-Guided Antibiotic Therapy after Stroke. Front Neurol. 2017 Apr 24;8:153. doi: 10.3389/fneur.2017.00153. eCollection 2017.</citation>
    <PMID>28484421</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2010</study_first_submitted>
  <study_first_submitted_qc>December 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2010</study_first_posted>
  <last_update_submitted>February 1, 2018</last_update_submitted>
  <last_update_submitted_qc>February 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Andreas Meisel</investigator_full_name>
    <investigator_title>Prof. Dr. Andreas Meisel, Charité University, Berlin, Germany (Center for Stroke Research Berlin CSB &amp; NeuroCure Clinical Research Center NCRC)</investigator_title>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>stroke-associated infections</keyword>
  <keyword>biomarkers</keyword>
  <keyword>PCT</keyword>
  <keyword>immune and infection parameters</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitonin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

